CEL SCI CORP (CVM) Chief Scientific Officer Eyal Talor acquired 1,165 common shares in a grant/award transaction on September 30, 2026. The reported price was $2.06 per share, and his direct holdings following the transaction were 10,483 shares. This was an award-related acquisition, not a market purchase.
CEL SCI CORP (symbol: CVM) is the issuer of record for a Form 4 filing submitted to the SEC. Cel-Sci Corp. Chief Financial Officer Patricia B. Prichep received a grant or award of 2,082 common shares on September 30, 2026; the transaction is listed at $2.06 per share. Her reported direct holding after the transaction was 19,571 shares. The acquisition is compensation-related, rather than a market transaction.
CEL SCI CORP (CVM) Chief Executive Officer and director Geert R. Kersten acquired 2,621 shares of Common Stock through a grant/award on September 30, 2026, at a reported $2.06 per share. After the transaction, he held 318,763 shares directly. A separate entry lists 311,547 shares as an indirect holding, with ownership described as Trustee.
CEL SCI CORP (CVM) reported that Chief Executive Officer and director Geert R. Kersten purchased 100,000 shares of restricted common stock directly from the company on August 25, 2026. The shares were bought at $1.38 per share, equal to the August 24, 2026 closing price, according to a footnote.
Following this purchase, Kersten’s reported direct holdings increased to 316,142 shares of common stock. He also reports 311,547 shares of common stock held indirectly as Trustee, shown as a separate holding entry.
CEL SCI CORP director Robert Eugene Watson reported a grant of 110,000 stock options on 2026-08-14. The options have an exercise price of $1.49 per share, an associated grant value of $0.01 per option, and expire on 2036-08-13. They vest in three equal annual installments starting one year after the grant date and are exercisable for 110,000 shares of common stock. Following this award, Watson holds 137,271 options directly.
CEL-SCI Corp (CVM) director Bruno Jean-Marie Baillavoine reported a grant of 110,000 stock options on 2026-08-14. The options have an exercise price of $1.49 per share, a nominal grant-date value of $0.01 per option, and expire on 2036-08-13. They vest in three equal annual installments commencing one year after the grant date. Following this grant, Baillavoine holds 138,021 options in total, all reported as directly owned.
CEL-SCI Corp reported that Senior Vice President John Cipriano received a grant of 80,000 stock options on 2026-08-14. The options have an exercise price of $1.49 per share, a stated value of $0.01 per option, and expire on 2036-08-13. Following this grant, Cipriano holds 118,010 options directly. According to the grant terms, the options vest in three equal annual installments starting one year after the grant date.
CEL-SCI Corp (CVM) reported that Chief Scientific Officer Talor Eyal received a grant of 250,000 options to acquire Common Stock. The options have an exercise price of $1.49 per share, expire on August 13, 2036, and vest in three equal annual installments starting one year after the grant date. Following this award, Eyal directly holds 331,625 options in total.
CEL SCI CORP Chief Financial Officer Patricia B. Prichep received a grant of stock options covering 225,000 shares of common stock. The options have an exercise price of $1.49 per share, a reported transaction price of $0.01 per option, and expire on August 13, 2036. They vest in three equal annual installments beginning one year after the grant date. Following this award, she holds 299,693 options in total.
CEL SCI CORP director and Chief Executive Officer Geert R. Kersten received a grant of 300,000 stock options on 2026-08-14. The options have an exercise price of $1.49 per share, a grant-date fair value of $0.01 per option, and expire on 2036-08-13. They vest in three equal annual installments starting one year after the grant date. Following this grant, Kersten directly holds 452,380 options in total.